SYS6010 Combined With Enlonstobart Versus Immunotherapy+ Platinum-based Chemotherapy for Patients With PD-L1-Positive Locally Advanced or Metastatic NSCLC（SYNSTAR 04）

NCT07633873 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

500

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG: SYS6010 injection
DRUG: Enlonstobart injection
DRUG: Tislelizumab injection
DRUG: Paclitaxel+Carboplatin or Pemetrexed + Cisplatin/Carboplatin

Sponsor

CSPC Megalith Biopharmaceutical Co.,Ltd.